Loading
LCB84 is an experimental antibody-drug conjugate from LigaChem Biosciences. It links an antibody aimed at TROP2 to an MMAE prodrug and is being studied in a phase 1/2 trial.
LCB84 is a TROP2-directed antibody-drug conjugate developed by LigaChem Biosciences. The NCT05941507 intervention record describes a human monoclonal antibody linked to a monomethyl auristatin E (MMAE) prodrug. This phase 1/2 study evaluates LCB84 alone and with an anti-PD-1 antibody in advanced solid tumours, with estimated enrolment of 300 and estimated primary completion in January 2027. The registry record was last posted on September 24, 2025 and still lists recruiting; this is the registered status, not confirmation that a site has an available slot. No efficacy results are recorded here.
TROP2-directed human monoclonal antibody linked to a monomethyl auristatin E (MMAE) prodrug, as described in the NCT05941507 intervention record. Connects to TROP2.
1.LCB84's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LCB84" OR ABSTRACT:"LCB84") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LCB84, not a curated reading list.
Shares LigaChem Biosciences and the tag pipeline.
Shares LigaChem Biosciences and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/